The Infamous Erlotinib Study
from OncoPharm Hosted by John Bossaer
An infamous study that led to a drug approval of limited benefit, but still made its way into an episode of Better Call Saul. Erlotinib + gemcitabine vs. gemcitabine: https://doi.org/10.1200/jco.2006.07.9525
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 14 minutes long.
When was this OncoPharm episode published?
This episode was published on August 4, 2022.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.